Syndax Pharmaceuticals SNDX Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's change in accrued liabilities?
- Syndax Pharmaceuticals (SNDX) reported change in accrued liabilities of -$28.35M in Q1 2026.
- How has Syndax Pharmaceuticals's change in accrued liabilities changed year-over-year?
- Syndax Pharmaceuticals's change in accrued liabilities decreased by 1019.2% year-over-year, from -$2.53M to -$28.35M.
- What is the long-term trend for Syndax Pharmaceuticals's change in accrued liabilities?
- Over 3 years (2021 to 2025), Syndax Pharmaceuticals's change in accrued liabilities has grown at a 147.9% compound annual growth rate (CAGR), from $2.77M to $42.17M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.